The Covid-19 pandemic has scythed vast sums from joint makers’ Q2 sales. But Medtronic’s summer earnings were better than those for its spring quarter.
Success or failure on the stock markets this year depended almost entirely on whether a company’s devices could be used to treat coronavirus patients.
Medtronic has had a poor quarter owing to the pandemic – but Zimmer’s has been even worse.
Sales of implants are set to fall sharply as non-urgent procedures are deferred.
The orthopaedics sector has seen several sizeable mergers over the past decade. Might it see more?
Intuitive Surgical makes the most money per employee – but the title of “most improved” goes to Philips.
The US FDA granted seven approvals in two days last week, including an eagerly awaited thumbs-up for Novartis’s gene therapy Zolgensma.
The J&J-Auris tie-up will yield a huge return for investors who went in big.